Advances in medical treatment of hypertrophic cardiomyopathy

Journal of Cardiology

Volumn 64, Issue 1, 2014, Pages 1-10

  Hamada, Mareomi ^a   Ikeda, Shuntaro ^a   Shigematsu, Yuji ^b  

^a Uwajima City Hospital   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta blocker; Calcium antagonist; Cibenzoline; Disopyramide; Hypertrophic cardiomyopathy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CIBENZOLINE; DISOPYRAMIDE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; IMIDAZOLE DERIVATIVE;

AGE DISTRIBUTION; ANTICHOLINERGIC EFFECT; DISEASE ASSOCIATION; DISEASE COURSE; FAMILY HISTORY; HEART DEATH; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART VENTRICLE WALL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MEDICAL HISTORY; PRESSURE GRADIENT; REVIEW; SUDDEN CARDIAC DEATH; ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; COMPLICATION; DEATH, SUDDEN, CARDIAC; DIASTOLE; FEMALE; HEART FAILURE; MALE; MIDDLE AGED; SYSTOLE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DEATH, SUDDEN, CARDIAC; DIASTOLE; DISEASE PROGRESSION; DISOPYRAMIDE; FEMALE; HEART FAILURE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84904066433     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.02.022     Document Type: Review

References (69)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958, 20:1-8.
2. Kim J.H., Malhotra R., Chiampas G., d'Hemecourt P., Troyanos C., Cianca J., Smith R.N., Wang T.J., Roberts W.O., Thompson P.D., Baggish A.L. Cardiac arrest during long-distance running races. N Engl J Med 2012, 366:130-140.
3. Maron M.S., Olivotto I., Betocchi S., Casey S.A., Lesser J.R., Losi M.A., Cecchi F., Maron B.J. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003, 348:295-303.
4. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982, 307:997-999.
5. Sherrid M., Delia E., Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988, 62:1085-1088.
6. Hamada M., Shigematsu Y., Ikeda S., Hara Y., Okayama H., Kodama K., Ochi T., Hiwada K. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997, 96:1520-1524.
7. Hamada M., Shigematsu Y., Inaba S., Aono J., Ikeda S., Watanabe K., Ogimoto A., Ohtsuka T., Hara Y., Higaki J. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction. Circ J 2005, 69:940-945.
8. Cazes M., Chassaing C., Martinet M., Cloarec A., Provost D., Boucher M., Duchêne-Marullaz P. Comparison of anticholinergic effects of cibenzoline, disopyramide, and atropine. J Cardiovasc Pharmacol 1990, 15:308-316.
9. Hamada M., Shigematsu Y., Hara Y., Suzuki M., Ohtsuka T., Hiasa G., Ogimoto A., Saeki H., Suzuki J., Hiwada K. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 2001, 65:531-538.
10. Maron B.J., Nichols P.F., Pickle L.W., Wesley Y.E., Mulvihill J.J. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 1984, 53:1087-1094.
11. Hecht G.M., Klues H.G., Roberts W.C., Maron B.J. Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. J Am Coll Cardiol 1993, 22:489-497.
12. Maron B.J., Roberts W.C., Epstein S.E. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982, 65:1388-1394.
13. McKenna W., Deanfield J., Faruqui A., England D., Oakley C., Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981, 47:532-538.
14. Maron B.J., Lipson L.C., Roberts W.C., Savage D.D., Epstein S.E. Malignant hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978, 41:1133-1140.
15. Maron B.J., Savage D.D., Wolfson J.K., Epstein S.E. Prognostic significance of 24-hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981, 48:252-257.
16. ten Cate F.J., Roelandt J. Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. Am Heart J 1979, 97:762-765.
17. Maron B.J., Epstein S.E., Roberts W.C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979, 43:1086-1102.
18. Fujiwara H., Onodera T., Tanaka M., Shirane H., Kato H., Yoshikawa J., Osakada G., Sasayama S., Kawai C. Progression from hypertrophic obstructive cardiomyopathy to typical dilated cardiomyopathy-like features in the end stage. Jpn Circ J 1984, 48:1210-1214.
19. Yutani C., Imakita M., Ishibashi-Ueda H., Hatanaka K., Nagata S., Sakakibara H., Nimura Y. Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy. Am Heart J 1985, 109:545-553.
20. Spirito P., Maron B.J., Bonow R.O., Epstein S.E. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987, 60:123-129.
21. Hamada M., Shigematsu Y., Fujiwara Y., Sumimoto T., Hiwada K., Kokubu T. Persistent elevation of cardiac enzymes in a patient with hypertrophic cardiomyopathy: with special reference to electrocardiographic, echocardiographic and 201-thallium myocardial scintigraphic findings. Jpn Circ J 1990, 54:354-360.
22. Hamada M. From typical hypertrophic cardiomyopathy to dilated cardiomyopathy-like features. J Jpn Soc Intern Med 1993, 82:188-193. [Japanese].
23. Hamada M., Shigematsu Y., Kuwahara T., Hara Y., Kodama K., Hiwada K. Transition from typical hypertrophic cardiomyopathy to end-stage congestive heart failure: 12-year follow-up study in 210 patients. Circulation 1997, 96(Suppl. I). I-462-3.
24. Biagini E., Coccolo F., Ferlito M., Perugini E., Rocchi G., Bacchi-Reggiani L., Lofiego C., Boriani G., Prandstraller D., Picchio F.M., Branzi A., Rapezzi C. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005, 46:1543-1550.
25. Harris K.M., Spirito P., Maron M.S., Zenovich A.G., Formisano F., Lesser J.R., Mackey-Bojack S., Manning W.J., Udelson J.E., Maron B.J. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216-225.
26. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104:557-567.
27. Chien K.R. Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. J Clin Invest 2003, 111:175-178.
28. Konno T., Shimizu M., Ino H., Matsuyama T., Yamaguchi M., Terai H., Hayashi K., Mabuchi T., Kiyama M., Sakata K., Hayashi T., Inoue M., Kaneda T., Mabuchi H. A novel missence mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. J Am Coll Cardiol 2003, 41:781-786.
29. Nagata S., Park Y.-D., Minamikawa T., Yutani C., Kamiya T., Nishimura T., Kozuka T., Sakakibara H., Nimura Y. Thallium perfusion and cardiac enzyme abnormalities in patients with familial hypertrophic cardiomyopathy. Am Heart J 1985, 109:1317-1322.
30. Jaffe A.S., Serota H., Grace A., Sobel B.E. Diagnostic changes in plasma creatine kinase isoforms early after the onset of acute myocardial infarction. Circulation 1986, 74:105-109.
31. Hamada M., Ohtani T., Sekiya M., Fujiwara Y., Sumimoto T., Hiwada K., Morita S., Tsukada H. Serum creatine kinase MM isoforms in hypertrophic cardiomyopathy. Clin Sci 1991, 81:723-726.
32. Kubo T., Kitaoka H., Yamanaka S., Hirota T., Baba Y., Hayashi K., Iiyama T., Kumagai N., Tanioka K., Yamasaki N., Matsumura Y., Furuno T., Sugiura T., Doi Y.L. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Am Coll Cardiol 2013, 62:1252-1259.
33. Jenab Y., Pourjafari M., Darabi F., Boroumaand M.A., Zoroufian A., Jalali A. Prevalence and determinants of elevated high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Cardiol 2014, 63:140-144.
34. Kawasaki T., Sugihara H. Subendocardial ischemia in hypertrophic cardiomyopathy. J Cardiol 2014, 63:89-94.
35. Marumoto K., Hamada M., Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris. Clin Sci 1995, 88:551-556.
36. Marumoto K., Aburaya M., Hamada M., Hiwada K. Augmented secretion of atrial and brain natriuretic peptides during dynamic exercise in patients with old myocardial infarction. Jpn Circ J 1995, 59:715-724.
37. Hamada M., Shigematsu Y., Kawakami H., Minamino N., Kangawa K., Matsuo H., Hiwada K. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-1, natriuretic peptides and noradrenaline. Clin Sci 1998, 94:21-28.
38. Levy D., Salomon M., D'Agostino R.B., Belanger A.J., Kannel W.B. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994, 90:1786-1793.
39. Das M.K., Khan B., Jacob S., Kumar A., Mahenthiran J. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 2006, 113:2495-2501.
40. Hamada M. Clinical evaluation of cardiomyopathies. Cardioangiology 2007, 61:459-466. [Japanese].
41. Hamada M., Izumi N., Yamane K., Ohshima K., Ishibashi K., Ohshima K., Ikeda S., Shigematsu Y. Diagnosis and management of hypertrophic cardiomyopathy. J Cardiol Jpn Ed 2009, 4:1-19. [Japanese].
42. Hamada T., Kubo T., Kitaoka H., Hirota T., Hoshikawa E., Hayato K., Shimizu Y., Okawa M., Yamasaki N., Matsumura Y., Yabe T., Takata J., Doi Y.L. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy. Clin Cardiol 2010, 33:E24-E28.
43. Goto D., Kinugawa S., Hamaguchi S., Sakakibara M., Tsuchihashi-Makaya M., Yokota T., Yamada S., Yokoshiki H., Tsutsui H. Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy: report from the registry data in Japan. J Cardiol 2013, 61:65-70. for the JCARE-CARD Investigators.
44. Harrison D.C., Braunwald E., Glick G., Mason D.T., Chidsey C.A., Ross J. Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964, 29:84-98.
45. Cherian G., Brockington I.F., Shah P.M., Oakley C.M., Goodwin J.F. Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy. Br Med J 1966, 1:895-898.
46. Adelman A., Shah P., Gramiak R., Wigle E. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 1970, 32:804-811.
47. Maron B.J., Bonow R.O., Cannon R.O., Leon M.B., Epstein S.E. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987, 316:780-789.
48. Doiuchi J., Hamada M., Ito T., Kokubu T. Comparative effects of calcium-channel blockers and beta-adrenergic blocker on early diastolic time intervals and A-wave ratio in patients with hypertrophic cardiomyopathy. Clin Cardiol 1987, 10:26-30.
49. Sueda S., Hamada M., Shigematsu Y., Kazatani Y., Sekiya M., Ochi T., Ito T., Kokubu T. Effect of propranolol on cardiac function and syncopal attack in patient with hypertrophic obstructive cardiomyopathy. J Cardiogr 1984, 14:597-604.
50. Kaltenbach M., Hopf R., Kober G., Bussmann W.D., Keller M., Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979, 42:35-42.
51. Hanrath P., Mathey D.G., Kremer P., Sonntag F., Bleifeld W. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol 1980, 45:1258-1264.
52. Bonow R.O., Frederick T.M., Bacharach S.L., Green M.V., Goose P.W., Maron B.J., Rosing D.R. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol 1983, 51:1386-1391.
53. Sumimoto T., Hamada M., Ohtani T., Suzuki M., Abe M., Matsuoka H., Fujiwara Y., Sekiya M., Hiwada K. Effect of disopyramide on left ventricular diastolic function in patients with hypertrophic cardiomyopathy: comparison with diltiazem. Cardiovasc Drugs Ther 1992, 6:425-428.
54. Gwathmey J.K., Warren S.E., Briggs G.M., Copelas L., Feldman M.D., Phillips P.J., Callahan M., Schoen F.J., Grossman W., Morgan J.P. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991, 87:1023-1031.
55. 2+: implications of mutations causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol 1997, 92(Suppl. 1):63-74.
56. Hamada M. Ia antiarrhythmic drugs for the treatment of hypertrophic cardiomyopathy. Jpn J Electrocardiol 2002, 22(Suppl. 3). S-3-42-56 [Japanese].
57. Pollick C., Giacomini K.M., Blaschke T.F., Nelson W.L., Turner-Tamiyasu K., Briskin V., Popp R.L. The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study. Circulation 1982, 66:447-453.
58. Sherrid M.V., Pearle G., Gunsburg D.Z. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998, 97:41-47.
59. Pollick C., Kimball B., Henderson M., Wigle E.D. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 1988, 62:1248-1251.
60. Sherrid M.V., Barac I., McKenna W.J., Elliott P.M., Dickie S., Chojnowska L., Casey S., Maron B.J. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005, 45:1251-1258.
61. Khoo K.C., Szuna A.J., Colburn W.A., Aogaichi K., Morganroth J., Brazzell R.K. Single-dose pharmacokinetics and dose proportionality of oral cibenzoline. J Clin Pharmacol 1984, 24:283-288.
62. Kondou N., Sakurai H., Toyada T., Yokoyama M., Daimon M., Fujimoto Y., Masuda Y. Cibenzoline relieves the pressure gradient of the left ventricular outflow tract stenosis with hypertrophic cardiomyopathy during bicycle ergometry. Shinzou 2001, 33:841-846. [Japanese].
63. Takada M., Fujita S., Katayama Y., Harano Y., Shibakawa M. The relationship between risk of hypoglycemia and use of cibenzoline and disopyramide. Eur J Clin Pharmacol 2000, 56:335-342.
64. Hamada M., Shigematsu Y., Ohshima K., Suzuki J., Ogimoto A., Ohtsuka T., Hara Y. Diagnostic usefulness of carotid pulse tracing in patients with hypertrophic obstructive cardiomyopathy due to midventricular obstruction - a comparison with idiopathic hypertrophic subaortic stenosis. Chest 2003, 124:1275-1283.
65. Hamada M., Aono J., Ikeda S., Watanabe K., Inaba S., Suzuki J., Ohtsuka T., Shigematsu Y. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy - its relationship to transmitral Doppler flow profiles. Circ J 2007, 71:1540-1544.
66. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., Grant S.R., Olson E.N. A calcineurin-dependent transcription pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
67. Blaustein M.P., Lederer W.J. Sodium/calcium exchange: its physiological implications. Physiol Rev 1999, 79:763-854.
68. 2+ exchange: molecular and pharmacological aspects. Circ Res 2001, 88:864-876.
69. Quednau B.D., Nicoll D.A., Philipson K.D. The sodium/calcium exchanger family-SLC8. Pflügers Arch 2004, 447:543-548.